Select Page

International

Lung Cancer Summit

Save The Date!

October 7: Lausanne University Hospital (CHUV)

Join us virtually online or on site in Lausanne!

 

REGISTRATION TO OPEN ON JULY 1st

 

 

 

Watch Last Year's Meeting

Alfredo Addeo, MD
Alfredo Addeo, MD

Alfredo Addeo, MD, is a Consultant Medical Oncologist at the University Hospital of Geneva, Switzerland. He is the author of numerous national and international peer-reviewed publications in renowned scientific journals, including first- and last-author publications in the Journal of Clinical Oncology, Annals of Oncology and Lancet Oncology. He has acted as a reviewer for several international scientific journals, including Journal of Thoracic Oncology and JAMA Oncology, and is an associate editor for Frontiers in Thoracic Oncology and guest editor for Precision Cancer Medicine. Dr. Addeo is an active ESMO member and a member of the EORTC lung group. He actively participates in ETOP (European Thoracic Oncology Platform) and SAKK (the Swiss Group for Clinical Cancer Research) and is a researcher and co-investigator of several national and international studies.

Solange Peters, MD-PhD
Solange Peters, MD-PhD

Solange Peters, MD-PhD, is Professor and chair of Medical Oncology as well as the Thoracic Malignancies programme in the department of oncology at Lausanne University Hospital, Switzerland. She has authored numerous peer-reviewed manuscripts and book chapters, and serves as deputy editor of the Journal of Thoracic Oncology, and on the editorial board of several other oncology journals. Professor Peters is active in the educational programs of the European Society for Medical Oncology (ESMO) and the International Association for the Study of Lung Cancer (IASLC), notably working as the current editor of the ESMO lung cancer clinical practice guidelines. She is the Chair of ESMO Women for Oncology Committee, and she is the youngest ESMO President ever, for a mandate in 2020-2021. She was also a member of the IASLC board of directors, and acts as vice president of the Swiss Group for Clinical Cancer Research lung group. She received both her doctorate in medicine and PhD from Lausanne University Hospital, Switzerland. After completing her clinical education in medical oncology and molecular biology in Switzerland and Italy, Professor Peters has specialized in thoracic tumors, lung cancer, and pleural tumors.

Follow Us For The Latest News on Twitter & LinkedIn

New study by @evelynnguyenxd, @charlesrudin and colleagues describes LSD1 as a regulator of MHC-I antigen presentation, and its inhibition has the potential to increase the anti-tumour immune response to ICB in #SCLC 🫁

See the study in @JTOonline ➡️ https://bit.ly/3Om00qO

Image for the Tweet beginning: New study by @evelynnguyenxd, @charlesrudin

💊 Drug approval news:

@EU_Commission approves atezolizumab as an adjuvant treatment, after complete resection & #chemotherapy for adults with #NSCLC whose tumours express PD-L1≥50% & who do not have #EGFR mutant or ALK+ NSCLC.

➡️ https://bit.ly/3O2ntgg

Image for the Tweet beginning: 💊 Drug approval news: 

@EU_Commission

Ramucirumab & pembrolizumab led to improved OS compared with SOC in people with advanced #NSCLC treated with #chemotherapy & #immunotherapy with acquired resistance to prior ICI 💊

See the study in @JCO_ASCO by @ReckampK, @DrRoyHerbstYale & colleagues ➡️ https://bit.ly/3aVXvgr

Image for the Tweet beginning: Ramucirumab & pembrolizumab led to

A new study looks at Vδ1 γδ T cells in human #lung tissues and the potential of integrating Vδ1 T cell biology into immunotherapeutic strategies for #NSCLC 🫁

Check it out in @NatureCancer by @dr_yinwu, @dhruva_biswas, @CharlesSwanton & colleagues ➡️ https://go.nature.com/3mgxfzQ

Image for the Tweet beginning: A new study looks at

What have we learned from trials testing the addition of #ICIs to first-line standard #chemotherapy for people with advanced #SCLC? 🤔

See this review discussing this very question & more in @FrontMedicine by Emilio F. Giunta, @gbanna74 & colleagues ➡️ https://bit.ly/3NC3q8m

Image for the Tweet beginning: What have we learned from

Study suggests selpercatinib can be administered to people with #NSCLC regardless of their prior #ICI status, despite incidences of treatment-related #hypersensitivity reactions 🫁

By @CarolineMccoach, @ChristianRolfo, Keunchil Park & colleagues ➡️ https://bit.ly/3wQpCpz

Image for the Tweet beginning: Study suggests selpercatinib can be

Results from phase II NADIM trial support neoadjuvant chemotherapy plus #nivolumab for resectable #NSCLC and the use of #ctDNA as a surrogate endpoint in terms of neoadjuvant treatment 🫁

See the study by Mariano Provencio, Atocha Romero & colleagues ➡️ https://bit.ly/3G5gznK

Image for the Tweet beginning: Results from phase II NADIM
Load More...